- call +1-201-465-4211
- email sales@mrinsights.biz
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection.
Scope of the Report:
This report studies the Acute Myeloid Leukemia market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Acute Myeloid Leukemia market by product type and applications/end industries.
Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.
North America is anticipated to be major contributor to this market accounting maximum percent of share in AML therapeutics market followed by Europe. Slow but constant growth in prevalence for AML in North America is anticipated to fuel the growth in acute myeloid leukemia (AML) therapeutics market. In Asia pacific region, China and India are anticipated to show high growth in acute myeloid leukemia (AML) therapeutics market due to new developments in healthcare infrastructure in the region.
The global Acute Myeloid Leukemia market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Acute Myeloid Leukemia.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others
Market Segment by Applications, can be divided into
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Acute Myeloid Leukemia Market Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia
1.2 Classification of Acute Myeloid Leukemia by Types
1.2.1 Global Acute Myeloid Leukemia Revenue Comparison by Types (2017-2023)
1.2.2 Global Acute Myeloid Leukemia Revenue Market Share by Types in 2017
1.2.3 Chemotherapy
1.2.4 Radiation Therapy
1.2.5 Stem Cell Transplant
1.2.6 Targeted Therapy
1.2.7 Others
1.3 Global Acute Myeloid Leukemia Market by Application
1.3.1 Global Acute Myeloid Leukemia Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 Retails Drug Stores
1.3.4 Ambulatory Care Centers
1.3.5 Oncology Centers
1.3.6 Clinics
1.4 Global Acute Myeloid Leukemia Market by Regions
1.4.1 Global Acute Myeloid Leukemia Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Acute Myeloid Leukemia Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Acute Myeloid Leukemia Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acute Myeloid Leukemia Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Acute Myeloid Leukemia Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acute Myeloid Leukemia Status and Prospect (2013-2023)
1.5 Global Market Size of Acute Myeloid Leukemia (2013-2023)
2 Manufacturers Profiles
2.1 Celgene Corporation
2.1.1 Business Overview
2.1.2 Acute Myeloid Leukemia Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Celgene Corporation Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.2 Cephalon
2.2.1 Business Overview
2.2.2 Acute Myeloid Leukemia Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Cephalon Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.3 Clavis Pharma
2.3.1 Business Overview
2.3.2 Acute Myeloid Leukemia Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Clavis Pharma Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.4 Eisai
2.4.1 Business Overview
2.4.2 Acute Myeloid Leukemia Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Eisai Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.5 Genzyme Corporation
2.5.1 Business Overview
2.5.2 Acute Myeloid Leukemia Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Genzyme Corporation Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.6 Sunesis Pharmaceuticals
2.6.1 Business Overview
2.6.2 Acute Myeloid Leukemia Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.7 Abbvie
2.7.1 Business Overview
2.7.2 Acute Myeloid Leukemia Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Abbvie Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.8 Astellas Pharma
2.8.1 Business Overview
2.8.2 Acute Myeloid Leukemia Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Astellas Pharma Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
2.9 CTI Biopharma Corp
2.9.1 Business Overview
2.9.2 Acute Myeloid Leukemia Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 CTI Biopharma Corp Acute Myeloid Leukemia Revenue, Gross Margin and Market Share (2016-2017)
3 Global Acute Myeloid Leukemia Market Competition, by Players
3.1 Global Acute Myeloid Leukemia Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Myeloid Leukemia Players Market Share
3.2.2 Top 10 Acute Myeloid Leukemia Players Market Share
3.3 Market Competition Trend
4 Global Acute Myeloid Leukemia Market Size by Regions
4.1 Global Acute Myeloid Leukemia Revenue and Market Share by Regions
4.2 North America Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
4.3 Europe Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
4.5 South America Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
5 North America Acute Myeloid Leukemia Revenue by Countries
5.1 North America Acute Myeloid Leukemia Revenue by Countries (2013-2018)
5.2 USA Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
5.3 Canada Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
5.4 Mexico Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
6 Europe Acute Myeloid Leukemia Revenue by Countries
6.1 Europe Acute Myeloid Leukemia Revenue by Countries (2013-2018)
6.2 Germany Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
6.3 UK Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
6.4 France Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
6.5 Russia Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
6.6 Italy Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Acute Myeloid Leukemia Revenue by Countries
7.1 Asia-Pacific Acute Myeloid Leukemia Revenue by Countries (2013-2018)
7.2 China Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
7.3 Japan Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
7.4 Korea Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
7.5 India Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
8 South America Acute Myeloid Leukemia Revenue by Countries
8.1 South America Acute Myeloid Leukemia Revenue by Countries (2013-2018)
8.2 Brazil Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
8.3 Argentina Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
8.4 Colombia Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Acute Myeloid Leukemia by Countries
9.1 Middle East and Africa Acute Myeloid Leukemia Revenue by Countries (2013-2018)
9.2 Saudi Arabia Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
9.3 UAE Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
9.4 Egypt Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
9.5 Nigeria Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
9.6 South Africa Acute Myeloid Leukemia Revenue and Growth Rate (2013-2018)
10 Global Acute Myeloid Leukemia Market Segment by Type
10.1 Global Acute Myeloid Leukemia Revenue and Market Share by Type (2013-2018)
10.2 Global Acute Myeloid Leukemia Market Forecast by Type (2018-2023)
10.3 Chemotherapy Revenue Growth Rate (2013-2023)
10.4 Radiation Therapy Revenue Growth Rate (2013-2023)
10.5 Stem Cell Transplant Revenue Growth Rate (2013-2023)
10.6 Targeted Therapy Revenue Growth Rate (2013-2023)
10.7 Others Revenue Growth Rate (2013-2023)
11 Global Acute Myeloid Leukemia Market Segment by Application
11.1 Global Acute Myeloid Leukemia Revenue Market Share by Application (2013-2018)
11.2 Acute Myeloid Leukemia Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 Retails Drug Stores Revenue Growth (2013-2018)
11.5 Ambulatory Care Centers Revenue Growth (2013-2018)
11.6 Oncology Centers Revenue Growth (2013-2018)
11.7 Clinics Revenue Growth (2013-2018)
12 Global Acute Myeloid Leukemia Market Size Forecast (2018-2023)
12.1 Global Acute Myeloid Leukemia Market Size Forecast (2018-2023)
12.2 Global Acute Myeloid Leukemia Market Forecast by Regions (2018-2023)
12.3 North America Acute Myeloid Leukemia Revenue Market Forecast (2018-2023)
12.4 Europe Acute Myeloid Leukemia Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Acute Myeloid Leukemia Revenue Market Forecast (2018-2023)
12.6 South America Acute Myeloid Leukemia Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Acute Myeloid Leukemia Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Acute Myeloid Leukemia Picture
Table Product Specifications of Acute Myeloid Leukemia
Table Global Acute Myeloid Leukemia and Revenue (Million USD) Market Split by P
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
